In chronic obstructive pulmonary disease (COPD), exacerbations (ECOPD), characterized
by an acute deterioration in respiratory symptoms, are fundamental events impacting …

Chronic obstructive pulmonary disease (COPD) is a global health problem, and since 2001,
the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has published its strategy …

Background Most guidelines recommend either a long-acting beta-agonist (LABA) plus an
inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice …

Rationale: The IMPACT (Informing the Pathway of Chronic Obstructive Pulmonary Disease
Treatment) trial demonstrated a significant reduction in all-cause mortality (ACM) risk with …

Background Blood eosinophil counts might predict response to inhaled corticosteroids (ICS)
in patients with chronic obstructive pulmonary disease (COPD) and a history of …

Background Treatment with inhaled glucocorticoids in combination with long-acting
bronchodilators is recommended in patients with frequent exacerbations of severe chronic …

Objective We performed a review of studies of fluticasone propionate (FP)/salmeterol
(SAL)(combination inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA)) in patients …

Chronic obstructive pulmonary disease (COPD) is the third most common cause of death in
the USA. In 2010, the cost of COPD in the USA was projected to be approximately US …

Description: This guideline is an official statement of the American College of Physicians
(ACP), American College of Chest Physicians (ACCP), American Thoracic Society (ATS) …

Severe exacerbations of COPD, ie, those leading to hospitalization, have profound clinical
implications for patients and significant economic consequences for society. The prevalence …